Endocrine Abstracts

Background: Recombinant human TSH (rhTSH) has become the modality of choice for radioiodine remnant ablation of residual thyroid cancer tissue in low-risk patients.Methods: The FACIT-F was administered from the early postoperative period to 9 months. Socio-demographic parameters, anxiety and depression scales were also evaluated. At 24 h, 48 h and d6 post-therapy, dose rate were measured. Using a simplified model, radiation exposure to public was estimat...